Brief Title
Quality of Life in Children Cured of Retinoblastoma
Official Title
Quality of Life in Children Cured of Retinoblastoma
Brief Summary
The aim of the study is to assess the quality of life of children who have been cured of
retinoblastoma - a malignant eye tumor. The study is questionnaire-based, and uses
standardized quality of life assessment tools.
Detailed Description
Retinoblastoma is the most common eye tumor of children. It can present in one eye
(unilateral) or in both eyes (bilateral). The bilateral form is always hereditary.
Retinoblastoma is a highly curable tumor. Using a combination of surgery, chemotherapy,
radiation and local treatment modalities to the eye, over 98% of patients are cured. This
means that most children diagnosed with retinoblastoma will become long-term survivors.
The use of surgery (taking out one eye), chemotherapy, and radiation may be associated with
long term side-effects, some of which may have significant impact on the quality of life of
the child. In addition, in case where the disease is hereditary, additional psychological
issues arise.
The aim of our study is to assess, in a comprehensive and standardized fashion, the long term
quality of life in children who were treated for retinoblastoma, and who are currently alive
and well.
The assessment will include the use of questionnaires that assess quality of life, as well as
participation in age-appropriate activities.
Each child, and his/her parent, will be interviewed and the questionnaires completed. The
process will take about one hour for each child. No risk or discomfort to the child is
involved.
Study Type
Observational
Primary Outcome
Change in quality of life
Condition
Retinoblastoma
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
35
Start Date
March 2006
Completion Date
December 2017
Primary Completion Date
December 2017
Eligibility Criteria
Inclusion Criteria:
- Past treatment for retinoblastoma
Gender
All
Ages
1 Year - 18 Years
Accepts Healthy Volunteers
No
Contacts
Michael Weintraub, MD, 972-2-6777408, [email protected]
Location Countries
Israel
Location Countries
Israel
Administrative Informations
NCT ID
NCT00278031
Organization ID
qolrb-HMO-CTIL
Responsible Party
Principal Investigator
Study Sponsor
Hadassah Medical Organization
Collaborators
Israel Cancer Association
Study Sponsor
Michael Weintraub, MD, Principal Investigator, Hadassah Medical Organization
Verification Date
October 2016